Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Epratuzumab by Gilead Sciences for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Epratuzumab is under clinical development by Gilead Sciences and currently in Phase III for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...